Different promising drugs targeting Akt have been developed and extensively investigated in the preclinical setting, and several clinical trials are now underway to assess the efficacy and safety of Akt inhibitors in different kinds of cancer [42,43]. This evidence concerns the gene AKT1 and cancer.